AB 1990 Advances Proposed Rules for Compounded Weight-Loss Medications On May 18, 2026, the California State Assembly ordered AB 1990 to third reading, advancing a bill that would impose sourcing, testing, recordkeeping, and advertising-disclosure requirements on certain compounded weight-loss drugs, including GLP-1 receptor agonists
[1] [2] Important safety considerations include a boxed warning for risk of thyroid C-cell tumors (contraindicated in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2)
If you reach a plateau or your goals change, we adjust your doseup, down, or steadyto keep your treatment working for you
IV THERAPY IN ANAHEIM Why is it Important and Beneficial to Your Health
12.2 Pharmacodynamics Typical actions of amphetamines include central nervous system stimulation and elevation of blood pressure
Approved for androgenetic alopecia, and also used off-label for telogen effluvium